We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Jun 2023
  • Code : CMI3634
  • Pages :110
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

The global GMP cell banking services market is estimated to be valued at US$ 803.9 million in 2023 and is expected to exhibit a CAGR of 13.5% during the forecast period (2023-2030).

Analysts’ Views on Global GMP Cell Banking Services Market:

The increasing technological advancement by key market players in the market to expand product poerfolio is expected to drive global GMP cell banking services market growth over the forecast period. For instance, in May 2022, NewBiologix SA, a technology innovation company, launched an advance novel technology platform for the manufacturing of gene and mammalian cell therapies. The company’s DNA-based platform is being developed to address key manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products

Figure 1. Global GMP Cell Banking Services Market Share (%), by Cell Type, 2023

GMP CELL BANKING SERVICES MARKET

To learn more about this report, request a free sample copy

Global GMP Cell Banking Services Market – Driver

Increasing inorganic growth strategies such as collaboration

The Increasing organic growth strategies such as product launch, inorganic growth strategies such as acquisition, collaboration, and increasing prevalence of cancer are act as an driver for the GMP cell service market. The increasing inorganic growth strategies such as collaboration by key market players to expand product portfolio is expected to drive the market growth over the forecast period. For instance, in June 2021, Heartseed Inc., a life science company, announced a collaboration with Novo Nordisk A/S, a healthcare company, for the development, manufacturing, and commercialization of Heartseed’s lead asset HS-001. HS-001 is an investigational stem cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure.

Increasing prevalence of cancer

The increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, in January 2022, according to data provided by American Cancer Society, a total of 1.9 million new cancer cases and 609,360 deaths from cancer are expected to occur in the U.S. in 2022, which is about 1,670 deaths a day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for cell banking which is expected to drive the market growth

Figure 2. Global GMP Cell Banking Services Market Value (US$ Million), by Region, 2023

GMP CELL BANKING SERVICES MARKET

To learn more about this report, request a free sample copy

Global GMP Cell Banking Services Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global GMP cell banking services market over the forecast period due to increasing inorganic growth strategies such as collaboration by key market players is expected to drive the market growth in North America region. For instance, in April 2020, Century Therapeutics, a developer of curative cell therapy, announced the collaboration with Bristol Myers Squibb Company, a pharmaceutical company, to develop and commercialize up to four induced pluripotent stem cell (“iPSC”) derived, engineered natural killer cell (“iNK”) and / or T cell (“iT”) programs for hematologic malignancies and solid tumors. This collaboration helps Century Therapeutics to further expand its pipeline of iPSC-derived cell therapy products for challenging hematological and solid tumor malignancies

Global GMP Cell Banking Services Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global GMP cell banking services market owing to a decrease in cancer patient visits to hospitals during COVID-19. For instance, on March 16, 2023, according to data provided by the National Library of Medicine, a decrease in the number of visits and hospital admission during the January–October 2020 period after the outbreak of the COVID-19 pandemic. The postponement or cancellation of these oncologic services negatively affected the patient’s outcome and the future burden of cancer disease. The mean change for oncologic visits throughout January–October 2020 compared to the pre-pandemic period was –37.8%, which reached its maximum decline in April –44.3%

GMP Cell Banking Services Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 803.9 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 13.5% 2030 Value Projection: US$ 1,950.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Cell Type: (Mammalian, Microbial, Insect, Yeast, Avian, Stem Cell Type, Others)
  • By End User: (Biopharmaceutical Companies Contract Manufacturing Organizations)
Companies covered:

WuXi AppTec Group, Charles River Laboratories International, Inc., Eurofins Scientific, Merck KGaA, Lonza Group Ltd., SGS Ltd., ViruSure GmbH, Austrianova, Goodwin Biotechnology Inc., and Paragon Bioservices, Inc. 

Growth Drivers:
  • Increasing organic growth strategies such as product launch
  • Increasing inorganic growth strategies such as acquisition and collaboration
  • Increasing prevalence of cancer
Restraints & Challenges:
  • High costs of cell banking service
  • Lack of skilled professionals
  • Stringent rules and regulations for cell banking process

Global GMP Cell Banking Services Market Segmentation:

The global GMP cell banking services market report is segmented into cell Type, End User, and Region

Based on Cell Type, the market is segmented into Mammalian, Microbial, Insect, Yeast, Avian, Stem Cell Type, and Others. Out of which, the mammalian segment is expected to hold a dominant position in the global GMP cell banking services market during the forecast period and this is owing to the increasing inorganic growth strategies such as acquisition by key market players for mammilian cell culture services

Based on End User, the market is segmented into Biopharmaceutical Companies and Contract Manufacturing Organizations. Out of which, the Biopharmaceutical Companies segment is expected to dominate the market over the forecast period and this is owing to the increasing inorganic growth strategies such as collaboration by key market players.

Based on Region, the market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Of which, North America is expected to dominate the market over the forecast period and this is attributed to the increasing inorganic growth strategies such as acquisition by key players in the region

Among all segmentation, by cell type segment has the highest potential due to the increasing adoption of organic growth strategies such as product launches by key market players to expand their product portfolio. For instance, in April 2022, Boehringer Ingelheim International GmbH, a pharmaceutical company, announced the launch of RenuTend, a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses

Global GMP Cell Banking Services Market Cross Sectional Analysis:

In End User segment, Contract Manufacturing Organizations segment holds a dominant position in North America region due to the increasing inorganic growth strategies such as acquisition by key players in the region is expected to drive the segment growth over the forecast period. For instance, in February 2021, Charles River Laboratories International, Inc., a U.S.-based contract manufacturing organization, announced the acquisition of Cognate BioServices, Inc., a premier, cell and gene therapy contract development and manufacturing organization (CDMO), for cell and gene therapy development

Global GMP Cell Banking Services Market: Key Developments

In September 2022, FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced the expansion of its large-scale microbial manufacturing facility located at the Billingham, U.K. campus

In April 2022, SGS, a U.S.-based contract manufacturing organization, announced a partnership with Liveome, a Korea-based drug developer, for the formulation, development, and clinical manufacture of a targeted release formulation containing lyophilized microbial cells and to build a cell bank, for the development and production process of drug

In April 2022, FUJIFILM Corporation, a contract development and manufacturing organization (CDMO), announced that it has completed the acquisition of Atara Biotherapeutics, Inc., a dedicated cell therapy manufacturing company, to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies

Global GMP Cell Banking Services Market: Key Trends

Increasing inorganic growth strategies such as partnership by key players in the market

Increasing inorganic growth strategies such as partnership by key players in the market to expand their product portfolio is expected to drive market growth over the forecast period. For instance, in January 2021, Sartorius AG, a life science company, announced a partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks to advance cell and gene therapy manufacturing and also scale-up of hMSC manufacturing for regenerative medicine

Global GMP Cell Banking Services Market: Restraint

High cost of cell banking services

The high costs of cell banking services, lack of skilled professionals, and stringent rules and regulations for the cell banking process are the major factors that can hamper the growth of the global GMP cell banking services market over the forecast period. For instance, in November 2022, according to the data provided by LifeCell International Pvt. Ltd., a stem cell bank, the annual average cost of stem cell banking was US$ 22.4 Mn to US$ 35 Mn. Thus high cost of cell banking service can hamper the growth of the market over the forecast period

Global GMP Cell Banking Services Market - Key Players

Major players operating in the global GMP cell banking services market include WuXi AppTec Group, Charles River Laboratories International, Inc., Eurofins Scientific, Merck KGaA, Lonza Group Ltd., SGS Ltd., ViruSure GmbH, Austrianova, Goodwin Biotechnology Inc., and Paragon Bioservices, Inc. 

Frequently Asked Questions

The global GMP cell banking services market is estimated to be valued at US$ 803.9 million in 2023 and is expected to exhibit a CAGR of 13.5% between 2023 and 2030.

Increasing organic growth strategies such as product launch, increasing inorganic growth strategies such as acquisition and collaboration, and increasing prevalence of cancer is expected to drive the market growth.

Mammalian is the leading cell type segment in the market

The high costs of cell banking service, lack of skilled professionals, and stringent rules and regulations for cell banking process

Major players operating in the market include WuXi AppTec Group, Charles River Laboratories International, Inc., Eurofins Scientific, Merck KGaA, Lonza Group Ltd., SGS Ltd., ViruSure GmbH, Austrianova, Goodwin Biotechnology Inc., and Paragon Bioservices, Inc.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo